Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SARS-CoV-2 vaccination response in patients with hematological disease
NL-OMON52047Phase 4Active, not recruiting
- Sponsor
- Maastricht University Medical Center+
- Start
- Mar 2021
- Countries
- 1
01
Overview
Phase 4, open-label trial of SARS-CoV-2 vaccine in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Maastricht University Medical Center+. Primary endpoint: Serologic response after vaccination. Started Mar 2021; status: active, not recruiting.
02
Drugs
SARS-CoV-2 vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON52047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52047.